CMS Urged To Cover Beta Amyloid PET Scans For Alzheimer's, But Cautiously
This article was originally published in The Pink Sheet Daily
Imaging stakeholders call for Medicare coverage of beta amyloid positron emission tomography scans to help diagnose and manage dementia patients, but clinical societies warn against using the technology as a screening tool for Alzheimer’s disease. CMS took comments through Nov. 8 on its ongoing national coverage analysis.
You may also be interested in...
At Lilly’s request, CMS has agreed to consider expanding the positron imaging tomography tracers that can be covered by Medicare to include agents for imaging beta-amyloid plaques when diagnosing dementia and other neurodegenerative disease.
Lilly’s Avid has gained approval for its imaging agent Amyvid, a new tool in the Alzheimer’s disease diagnosis arsenal.
With a CE mark in hand, Exonhit is training its sights on the U.S. market. A 160-patient pilot study conducted through the Cleveland Clinic completed enrollment a few weeks ago.